Document is current

Any future updates will be listed below

Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

Crossref DOI link: https://doi.org/10.1007/s10198-015-0726-5

Published Online: 2015-09-04

Published Print: 2016-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark